ArticleTransfusion2026
Elevating the standards of hypofibrinogenemia in trauma: Higher thresholds of admission fibrinogen predict mortality and organ dysfunction.
Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe precise thresholds at which admission fibrinogen predicts mortality and organ dysfunction in trauma patients are unknown. STUDY DESIGN AND
methodsRetrospective study at a single trauma center. INCLUSION CRITERIA: 18-89 years, traumatic mechanism, transported from scene, and fibrinogen obtained within 30-min of arrival. Admission fibrinogen: <150, 150-199, 200-249, and ≥250 mg/dL. PRIMARY OUTCOME: 28-day mortality. Multivariable logistic regression analysis described the risk of 28-day mortality by fibrinogen levels. SECONDARY OUTCOMES: 24-h mortality, acute kidney injury (AKI) and acute respiratory distress syndrome (ARDS). The optimal threshold of admission fibrinogen associated with AKI and ARDS was determined. Results reported as odds ratio (OR) with 95% confidence interval (CI).
resultsTwo thousand five hundred and five patients included. Admission fibrinogen: 94 (3.8%) <150 mg/dL, 225 (9.0%) 150-199 mg/dL, 533 (21.3%) 200-249 mg/dL, and 1653 (66.0%) ≥250 mg/dL. Twenty-eight-day mortality occurred in 239/2505 (9.5%), and 114/2505 (4.6%) died within 24 h. Fibrinogen <150 mg/dL (OR: 11.86, 95% CI: 5.80-24.26; p < .001) and fibrinogen 150-199 mg/dL (OR: 2.20, 95% CI 1.22-3.96; p = .009) were associated with 28-day mortality. Admission fibrinogen <150 and 150-200 mg/dL were also associated with 24 h mortality. The optimal cutoff of fibrinogen and AKI was <238 mg/dL, which predicted AKI (OR: 2.45, 95% CI: 1.4-4.4). The optimal cutoff of fibrinogen and ARDS was <235 mg/dL, and predicted ARDS (OR: 1.9, 95% CI: 1.01-3.55).
conclusionAdmission hypofibrinogenemia <200 mg/dL is associated with 28-day and 24 h mortality in trauma patients. Admission fibrinogen is also a marker for post-traumatic AKI and ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.